CK19, P53,P63,EMA ,P170蛋白在甲状腺乳头状癌中的表达及病理意义

Expression of CK19,P53,P63,EMA,and P170 protein in papillary thyroid carcinoma

关键词:  甲状腺乳头状癌  CK19  P53  P63  EMA  P170  免疫组织化学

Key words:  papillary thyroid carcinoma  CK19  P53  P63  EMA  P170  immunohistochemistry

摘要:

［目的］ 评价CK19,P53,P63,EMA在鉴别甲状腺良恶性（乳头状癌）病变中的临床应用价值；了解甲状腺乳头状癌P170蛋白表达的意义。［方法］ 通过免疫组织化学 方法，检测CK19,P53,P63,EMA,及 P170蛋白在38例甲状腺乳头状癌和38例甲状腺良性病变中的表达。［结果］CK19、P53、P63、EMA在甲状腺乳头状癌和良性病变中的阳性率分别为92.1%(35/38)和2.6% (1/38) (P<0.005），89.5% (34/38)和18.4% (7/38) (P<0.005）， 23.7%(9/38)和10.5%(4/38)（P>0.1），34.2%(13/38)和50%(19/38)(P>0.1）。甲状腺乳头状癌中P170表达阳性率为57.9%(22/38)。［结论］(1)CK19和P53是甲状腺乳头状癌病理诊断中非常有价值的辅助诊断指标。(2)甲状腺乳头状癌中P170表达的阳性率与CK19的阳性程度密切相关。

Abstract:

［Objective］To estimate the clinical value of CK19、P53、P63、EMA on distinguishing benign and malignant thyroid disease especially for PTC. To know more about the meaning of P170’s expression in PTC. ［Methods］By immunohistochemical methodcalled Elivision, CK19、P53、P63、EMA、P170 are examined respectively in 38 PTC patients and in 38 thyroid benign disease patients.［Results］CK19、P53、P63、EMA expression rates in PTC and benign disease of thy roid were 92.1%(35/38) and 2.6% (P<0.005) ; 89.5% (34/38) and 18.4% (7/38)(P<0.005); 23.7% (9/38) and 10.5%(4/38)(P>0.1); 34.2%(13/38) and 50%(19/38)(P>0.1);In 22 cases of the PTC group ,the positive rate of P170 is 57.9%. ［Conclusions］(1) CK19 and P53 are valuable assistant diagnostic points for PTC pathological diagnosis. (2) The positive rate of P170 expression is high in PTC and closely related to CK19.